PixarBio (PixarBio) Capex-to-Operating-Income : 0.00 (As of Sep. 2016)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

PixarBio's Capital Expenditure for the three months ended in Sep. 2016 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2016 was $-0.05 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

PixarBio Capex-to-Operating-Income Historical Data

The historical data trend for PixarBio's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Capex-to-Operating-Income Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Capex-to-Operating-Income

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Capex-to-Operating-Income	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of PixarBio's Capex-to-Operating-Income

For the Biotechnology subindustry, PixarBio's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PixarBio's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PixarBio's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where PixarBio's Capex-to-Operating-Income falls into.

PixarBio Capex-to-Operating-Income Calculation

PixarBio's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2015 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-0.095
	=	N/A

PixarBio's Capex-to-Operating-Income for the quarter that ended in Sep. 2016 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-0.047
	=	N/A

PixarBio (GREY:PXRB) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

PixarBio Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of PixarBio's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

PixarBio (PixarBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.